Skip to main content
logo
Evogene Ltd. (EVGN)
NASDAQ: EVGN · Real-Time Price · USD
1.370
-0.080 (-5.52%)
At close: Jul 11, 2025, 4:00 PM
1.420
+0.050 (3.65%)
After-hours: Jul 11, 2025, 7:10 PM EDT

Evogene Revenue

Evogene had revenue of $2.44M in the quarter ending March 31, 2025, a decrease of -41.67%. This brings the company's revenue in the last twelve months to $6.77M, down -26.38% year-over-year. In the year 2024, Evogene had annual revenue of $8.51M with 50.90% growth.

Revenue (ttm)
$6.77M
Revenue Growth
-26.38%
P/S Ratio
1.86
Revenue / Employee
$57,821
Employees
117
Market Cap
12.58M

Revenue Chart

Revenue History

Fiscal Year End Revenue Change Growth
Dec 31, 2024 8.51M 2.87M 50.90%
Dec 31, 2023 5.64M 3.97M 236.72%
Dec 31, 2022 1.68M 745.00K 80.11%
Dec 31, 2021 930.00K -110.00K -10.58%
Dec 31, 2020 1.04M 287.00K 38.11%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 410.06B
Johnson & Johnson 89.33B
Merck & Co. 63.92B
AbbVie 57.37B
AstraZeneca 54.98B
Novartis AG 53.22B
Eli Lilly and Company 49.00B
Novo Nordisk 43.92B
Revenue Rankings

EVGN News

More News